StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
BBIOBullishIndustry Newsnews
High materiality9/10

BridgeBio presents ESC 2026 data showing durable, reversal signals for acoramidis

Aug 30, 2026, 10:03 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong positive efficacy signals and durable outcomes in a high-need indication typically support multiple expansion and potential near-term option value; data depth (LV function, DLDCVH, mortality) provides tangible fundamentals.

AI summary

What happened, with direct paths to the underlying reporting

BridgeBio unveiled ESC 2026 ATTRibute-CM data for acoramidis, including CMR substudy and open-label extension. The results show potential reversal of cardiac disease progression in a meaningful subset and durable benefits out to 54 months, with mortality and hospitalization trends favoring continuous treatment, offering a potential long‑term growth catalyst for BBIO.

  • BridgeBio presents ATTRibute-CM data at ESC 2026 for acoramidis (Attruby).
  • Completer analysis: 54% LV function improvement vs 20% placebo at Month 30.
  • Through Month 42, 53% continuous acoramidis improved LV function.
  • Acoramidis reduced DLDCVH to 7.5% vs 11.7% placebo through Month 30.
  • Month 54: ACM lower in p.Val142Ile subgroup with continuous treatment.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event